If you would like to read Public Comments or to submit ones relative to the 28 November 2021 Antimicrobial Drugs Advisory Committee: Notice of Meeting; Establishment of a Public Docket: Request for Comments (/document/FDA-2021-N-0758-0012), please do so. I (Michael Waters) and my coauthors submitted our preprint on 4 November 2021 and a summary with minor corrections (Michael Dee Waters) on 9 Nov 2021.

Here is the URL for the latter submission:

Docket No. FDA-2021-N-0758

FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment

If you go to regulations.gov and enter the Docket Number FDA-2021-N-0758 and look under the tab Comments, you will see the Public Comments that have been posted so far. #3 is from Ron Swanstrom and #5 is from me. Biochemistry is important in today’s world. All the best to the Department!

Ron Swanstrom PhD submitted his comments and “he should be commended!”

— Michael Dee Waters, PhD, UNC, Biochemistry, 1969. (11/12/2021)

---

Update on Dec. 23, 2021

The Pills to Fight COVID-19

The FDA has approved antiviral pills you take once you’ve been infected to fight COVID-19. Learn more about the pills and how UNC researchers helped with testing the safety and efficacy of molnupiravir, developed by Ridgeback Biotherapeutics and Merck.